|
1
|
Hou L, Ji BT, Blair A, Dai Q, Gao YT and
Chow WH: Commuting physical activity and risk of colon cancer in
Shanghai, China. Am J Epidemiol. 160:860–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li J, Hou N, Faried A, Tsutsumi S,
Takeuchi T and Kuwano H: Inhibition of autophagy by 3-MA enhances
the effect of 5-FU-induced apoptosis in colon cancer cells. Ann
Surg Oncol. 16:761–771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Talmon G and Wang J: MicroRNA-587
antagonizes 5-FU-induced apoptosis and confers drug resistance by
regulating PPP2R1B expression in colorectal cancer. Cell Death Dis.
6:e18452015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laurent-Puig P, Cayre A, Manceau G, Buc E,
Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, et al:
Analysis of PTEN, BRAF, and EGFR status in determining benefit from
cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin
Oncol. 27:5924–5930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noordhuis MG, Eijsink JJH, Ten Hoor KA,
Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de
Bock GH, et al: Expression of epidermal growth factor receptor
(EGFR) and activated EGFR predict poor response to (chemo)radiation
and survival in cervical cancer. Clin Cancer Res. 15:7389–7397.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Y, Tan B, Kuo MS, Liu L and Breyer
MD: Abstract 5439: Metabolomic study of EGFR drug resistance
mechanisms. Cancer Res. 74:(Suppl 19). S5439. 2014. View Article : Google Scholar
|
|
9
|
Taylor TE, Furnari FB and Cavenee WK:
Targeting EGFR for treatment of glioblastoma: Molecular basis to
overcome resistance. Curr Cancer Drug Targets. 12:197–209. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li J, Ji Z, Qiao C, Qi Y and Shi W:
Overexpression of ADAM9 promotes colon cancer cells invasion. J
Invest Surg. 26:127–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia AY, Castillo-Martin M, Bonal DM,
Sánchez-Carbayo M, Silva JM and Cordon-Cardo C: MicroRNA-126
inhibits invasion in bladder cancer via regulation of ADAM9. Br J
Cancer. 110:2945–2954. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu R, Gu J, Jiang P, Zheng Y, Liu X,
Jiang X, Huang E, Xiong S, Xu F, Liu G, et al: DNMT1-microRNA126
epigenetic circuit contributes to esophageal squamous cell
carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res.
21:854–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blobel CP: ADAMs: Key components in EGFR
signalling and development. Nat Rev Mol Cell Biol. 6:32–43. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pham NA, Schwock J, Iakovlev V, Pond G,
Hedley DW and Tsao MS: Immunohistochemical analysis of changes in
signaling pathway activation downstream of growth factor receptors
in pancreatic duct cell carcinogenesis. BMC Cancer. 8:432008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Işeri OD, Kars MD, Arpaci F and Gündüz U:
Gene expression analysis of drug-resistant MCF-7 cells:
Implications for relation to extracellular matrix proteins. Cancer
Chemother Pharmacol. 65:447–455. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kyula JN, Van Schaeybroeck S, Doherty J,
Fenning CS, Longley DB and Johnston PG: Chemotherapy-induced
activation of ADAM-17: A novel mechanism of drug resistance in
colorectal cancer. Clin Cancer Res. 16:3378–3389. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sarkar FH, Li Y, Wang Z, Kong D and Ali S:
Implication of microRNAs in drug resistance for designing novel
cancer therapy. Drug Resist Updat. 13:57–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park SL, Cho TM, Won SY, Song JH, Noh DH,
Kim WJ and Moon SK: MicroRNA-20b inhibits the proliferation,
migration and invasion of bladder cancer EJ cells via the targeting
of cell cycle regulation and Sp-1-mediated MMP-2 expression. Oncol
Rep. 34:1605–1612. 2015.PubMed/NCBI
|
|
20
|
Sarver AL, French AJ, Borralho PM,
Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM,
Boardman LA, Cunningham JM, et al: Human colon cancer profiles show
differential microRNA expression depending on mismatch repair
status and are characteristic of undifferentiated proliferative
states. BMC Cancer. 9:401. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng
Q, Sun J and Wang T: MicroRNA-425-5p regulates chemoresistance in
colorectal cancer cells via regulation of Programmed Cell Death 10.
J Cell Mol Med. 20:360–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giacchetti S, Itzhaki M, Gruia G, Adam R,
Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic
F, Jasmin C, et al: Long-term survival of patients with
unresectable colorectal cancer liver metastases following
infusional chemotherapy with 5-fluorouracil, leucovorin,
oxaliplatin and surgery. Ann Oncol. 10:663–669. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Linda Y, Narasimhaswamy B and David HB:
MicroRNA and colorectal cancer. Dig Liver Dis Off J Ital Soc
Gastroenterol Ital Assoc Study Liver. 44:66–70. 2012.
|
|
24
|
Gregersen LH, Jacobsen AB, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-145 targets YES and STAT1 in colon
cancer cells. PLoS One. 5:e88362010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Valeri N, Braconi C, Gasparini P, Murgia
C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat
F, et al: MicroRNA-135b promotes cancer progression by acting as a
downstream effector of oncogenic pathways in colon cancer. Cancer
Cell. 25:469–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmed FE: miRNA as markers for the
diagnostic screening of colon cancer. Expert Rev Anticancer Ther.
14:463–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saleiban A, Faxälv L, Claesson K, Jönsson
JI and Osman A: miR-20b regulates expression of
proteinase-activated receptor-1 (PAR-1) thrombin receptor in
melanoma cells. Pigment Cell Melanoma Res. 27:431–441. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee H, Kim C, Ku JL, Kim W, Yoon SK, Kuh
HJ, Lee JH, Nam SW and Lee EK: A long non-coding RNA snaR
contributes to 5-fluorouracil resistance in human colon cancer
cells. Mol Cells. 37:540–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W,
Jiang X, Zhang C and Qu J: MicroRNA-195 chemosensitizes colon
cancer cells to the chemotherapeutic drug doxorubicin by targeting
the first binding site of BCL2L2 mRNA. J Cell Physiol. 230:535–545.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mussnich P, Rosa R, Bianco R, Fusco A and
D'Angelo D: MiR-199a-5p and miR-375 affect colon cancer cell
sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther
Targets. 19:1017–1026. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
West CM, Joseph L and Bhana S: Epidermal
growth factor receptor-targeted therapy. Br J Radiol. 81:S36–S44.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moroni M, Veronese S, Benvenuti S,
Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M,
Siena S and Bardelli A: Gene copy number for epidermal growth
factor receptor (EGFR) and clinical response to antiEGFR treatment
in colorectal cancer: A cohort study. Lancet Oncol. 6:279–286.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Patel BB, Sengupta R, Qazi S, Vachhani H,
Yu Y, Rishi AK and Majumdar AP: Curcumin enhances the effects of
5-fluorouracil and oxaliplatin in mediating growth inhibition of
colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer.
122:267–273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Engel J, Richters A, Getlik M, Tomassi S,
Keul M, Termathe M, Lategahn J, Becker C, Mayer-Wrangowski S,
Grütter C, et al: Targeting drug resistance in EGFR with covalent
inhibitors: A structure-based design approach. J Med Chem.
58:6844–6863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hirao T, Nanba D, Tanaka M, Ishiguro H,
Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M and Higashiyama S:
Overexpression of ADAM9 enhances growth factor-mediated recycling
of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell
Res. 312:331–339. 2006.PubMed/NCBI
|
|
36
|
Hamada S, Satoh K, Fujibuchi W, Hirota M,
Kanno A, Unno J, Masamune A, Kikuta K, Kume K and Shimosegawa T:
MiR-126 acts as a tumor suppressor in pancreatic cancer cells via
the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
